SCYX - Scynexis stock falls 17% despite fungal infection drug showing promise in interim data from 2 late-stage studies

Scynexis (NASDAQ:SCYX) said interim data from two ongoing phase 3 studies of oral ibrexafungerp showed improvement in ~61% of patients with fungal infection. Data from 131 patients — 113 patients in the phase 3 trial called FURI and 18 patients from the phase 3 study, dubbed CARES — was evaluated, who had completed their treatment as of October 2021, including recent review of 47 patients. The company said 61.1% (80/131) patients achieved a complete or partial response, or clinical improvement. About 22.1%, or 29 patients achieved stable disease, which according to the company was a favorable outcome in patients with severe progressive fungal infections. Scynexis (SCYX) added that 11.5% of the total patients were considered no response, which included two patients who died of an underlying condition unrelated to the treatment. “These results further support ibrexafungerp’s potential to treat complex fungal infections in the hospital setting,” said Scynexis Chief Medical Officer David Angulo.

For further details see:

Scynexis stock falls 17% despite fungal infection drug showing promise in interim data from 2 late-stage studies